May 14th 2024
The duration of neoadjuvant chemotherapy may be optimized via MRI guidance for the treatment of hormone receptor-negative/HER2-positive breast cancer.
Patient, Provider and Caregiver Connection™: Addressing Patient Concerns During the Treatment and Management of HR+/HER2- Breast Cancer
View More
Patient, Provider, and Caregiver Connection: Addressing Pediatric and AYA Patient Concerns While Managing Hodgkin Lymphoma
View More
Oncology Consultations®: Next Generation SERDs—Key Data and Practical Takeaways for the Community Physician
View More
Multidisciplinary Management of TNBC: Immunotherapy, PARP, TROP2, Oh My!
View More
Medical Crossfire®: Leveraging Multidisciplinary Teams in Early–Stage Breast Cancer When the Goal is Cure
View More
23rd Annual International Congress on the Future of Breast Cancer® East
July 19-20, 2024
Register Now!
Community Practice Connections™: 14th Annual International Symposium on Ovarian Cancer and Other Gynecologic Malignancies
View More
Community Practice Connections™: The Advent of TROP2-Targeted Treatment Approaches in HR+/HER2- Breast Cancer
View More
Community Practice Connections™: Controversies and Conversations About HER2- Expressing Breast Cancer…Advances in Management of HER2-Low to -Positive Disease
View More
Show Me the Data™: Do We Have Sea Change for Novel Approaches in HR+/HER2- Breast Cancer? CDK, PI3K/AKT, ADC, and Next-Gen SERD Strategies Assessed
View More
Cancer Summaries and Commentaries™: Clinical Updates from Chicago in Breast Cancer
View More
8th Annual School of Nursing Oncology™
August 10, 2024
Register Now!
Applying New Evidence in Multiple Myeloma Care from Frontline to R/R Disease
View More
42nd Annual CFS®: Innovative Cancer Therapy for Tomorrow®
November 13-15, 2024
Register Now!
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?
View More
Medical Crossfire®: How Do Clinicians Integrate the Latest Evidence in Treating Ovarian Cancer to Personalize Care?
View More
Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!
View More
Medical Crossfire: How Has Iron Supplementation Altered Treatment Planning for Patients with Cancer-Related Anemia?
View More
42nd Annual Miami Breast Cancer Conference®
March 6 - 9, 2025
Register Now!
The Evolving Tool Box in Advanced HR+/HER2– Breast Cancer: What You Need to Know About Next-Generation SERDs, PI3K/AKT, ADCs, CDK4/6 and Beyond…
View More
Coffee Talk™: Navigating the Impact of HER2/3, TROP2, and PARP from Early Stage to Advanced Breast Cancer Care
View More
Analysis Provides Reassurance on Radiation's Impact on Lymphedema Risk
September 18th 2014A new analysis of the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-32 trial presented at the ASTRO 56th Annual Meeting offers substantial evidence that treatment with radiation therapy does not increase the incidence of lymphedema in patients with node-negative breast cancer.
Goserelin When Combined With Chemotherapy a Safe Option to Protect Fertility
September 5th 2014Women who received the hormone suppressor goserelin (Zoladex) along with their chemotherapy were significantly less likely to develop premature ovarian failure and were more likely to have successful pregnancies, than women who received chemotherapy alone, according to findings from the federally funded phase III S0230/POEMS clinical trial.
Evidence-Based Information Should Guide Prophylactic Mastectomy Decisions
September 4th 2014One of the first studies to prospectively examine women's breast surgery preferences has revealed that newly diagnosed women with breast cancer who decide to undergo contralateral prophylactic mastectomy (CPM) aren't relying on evidence-based information, highlighting the need for interdisciplinary patient education and communication.
"Angelina Jolie Effect" Draws Attention to Genetic Counselor Model
September 3rd 2014With more and more data supporting the association between actress Angelina Jolie's double mastectomy and an increase in the amount of patients seeking genetic testing, the attention is on genetic counselors to improve their intake model to more efficiently handle the increased demand.
Bilateral Mastectomy Rates on the Rise, Particularly Among Younger Women
September 3rd 2014A new study has shown that while there was an increase in the percentage of women diagnosed with early-stage breast cancer undergoing a double mastectomy, the increase was not associated with a lower risk of death compared to breast-conserving surgery plus radiation.
Three-Time Cancer Survivor Inspires Others With Her Courage
August 29th 2014Every year, Cancer Hope Network (CHN) awards a group or individual who has made a difference through their own courageous battle with cancer, or who has helped others through the ordeal of treatment. The Committee evaluates nominees on how they made a difference through a display of courage, spirit, inspiration, or support in the battle with cancer.
Is it Time to Think Outside the Box?: New Approaches to Genetics Services
August 28th 2014The demand for genetic services has never been greater. Vast advances in genetic technology, Angelina Jolie's disclosure that she is a BRCA mutation carrier, and the Supreme Court ruling on gene patents have hurled genetic services into the mainstream. Since the Supreme Court ruling last year, the cost of germline (hereditary) genetic testing has plummeted and now includes panels of genes.
Trial Suggests Potential Role for DHEA in Relieving Vaginal Symptoms
August 28th 2014A randomized multi-center trial examining the efficacy of adding the prohormone dehydroepiandosterone (DHEA) to a vaginal bioadhesive moisturizer in postmenopausal survivors of breast or gynecologic cancer has found that daily rather than as-needed use of such a moisturizer significantly relieves symptoms of vaginal atrophy in these women, and that when DHEA is added, survivors report significant improvements in sexual desire, arousal, pain, and overall sexual function.
Dr. Jagsi Discusses the Benefits of Hypofractionated Radiotherapy for Breast Cancer
August 21st 2014Reshma Jagsi, MD, DPhil, associate professor, Department of Radiation Oncology, University of Michigan Health System, discusses the benefits of hypofractionated radiotherapy for patients with breast cancer.
Most Patients Don't Opt for Breast Reconstruction and They Don't Regret It
August 20th 2014Even though universal coverage for postmastectomy breast reconstruction is mandated, a new study has found that the majority of women are deciding not to undergo breast reconstruction surgery following a mastectomy.
Can NSAIDs Help Prevent Recurrence in Overweight Breast Cancer Patients?
August 19th 2014Researchers at The University of Texas at Austin have found that postmenopausal overweight or obese breast cancer patients receiving hormone therapy as part of their treatment who use nonsteroidal anti-inflammatory drugs (NSAIDs) have significantly lower breast cancer recurrence rates and a sizable delay in time to cancer recurrence.
Arin Hanson Discusses the Results of a National Needs Assessment of Young Women with Breast Cancer
August 13th 2014Arin Ahlum Hanson, MPH, CHES, manager, Young Women's Initiative, Living Beyond Breast Cancer, discusses the results of a national needs assessment of young women with breast cancer that was conducted by the Young Women's Initiative.
Exercise Lowers Breast Cancer Risk, But Benefits Fade When Activity Stops
August 12th 2014A new study has found that postmenopausal women who undertook regular physical activity equivalent to at least 4 hours of walking per week in the last 4 years had a lower risk for invasive breast cancer compared with women who exercised less during those 4 years.
PALB2, BRCA2 Gene Mutations Confer Similar Breast Cancer Risk
August 8th 2014Women harboring a loss-of-function mutation in the PALB2 gene demonstrated an increased risk of developing breast cancer that was similar to the predisposition seen with mutations in the infamous BRCA gene, according to a study published in The New England Journal of Medicine (NEJM).
Acupuncture Offers Quality-of-Life Benefits for Patients Taking AIs
July 30th 2014A new study led by researchers at the Perelman School of Medicine at the University of Pennsylvania has shown that electroacupuncture produces significant improvements in fatigue, anxiety, and depression in as little as 8 weeks for early-stage breast cancer patients experiencing joint pain related to the use of aromatase inhibitors (AIs).
Trastuzumab-Associated Cardiac Events Reversible, Outweighed by Benefits
July 18th 2014Cardiac events associated with trastuzumab (Herceptin) are mostly reversible and outweighed by significant extensions in overall survival (OS) and progression-free survival (PFS) for patients with HER2-positive breast cancer